InvestorsHub Logo
Followers 32
Posts 10384
Boards Moderated 0
Alias Born 04/20/2016

Re: surf1944 post# 2707

Sunday, 11/19/2017 10:13:14 AM

Sunday, November 19, 2017 10:13:14 AM

Post# of 5006
As I understand it the financing has not been done. There is a hope that the S1 gets pulled and the company can raise it enough funds without institutions. No doubt in my mind institutions that funded VTGN are running a massive short and driving price down.

The game is simple, they know VTGN needs money so they profit 2 ways. Driving the price down while shorting against their own clients positions and filling that short at lower prices through another round of funding while at the same time buying more shares at a further ridiculous discounted price.

The asset AV101 could easily be worth 2 billion dollars or more yet the company has a 30 million dollar market cap. Naurex drug sold for 650 mil cash plus 1 billion dollars in backend milestones and that drug needs to be administered through IV

The National Institute of Health funded Phase 2a and those results are expected Febuary 2018.

Maybe a strategic partnership with big pharma might be the best route.

There is now way that the stock trades 10 times its previous highest volume on great news that the FDA approved an approved compound for trial and the stock goes down.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VTGN News